MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Intercept Pharmaceuticals Company Profile (NASDAQ:ICPT)

Consensus Ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) (?)
Ratings Breakdown: 2 Sell Rating(s), 5 Hold Rating(s), 12 Buy Rating(s)
Consensus Rating:Buy (Score: 2.53)
Consensus Price Target: $219.64 (46.55% upside)

Analysts' Ratings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Show:
DateFirmActionRatingPrice TargetActions
6/24/2016WedbushReiterated RatingOutperform$239.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Robert W. BairdReiterated RatingOutperform$332.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Needham & Company LLCReiterated RatingBuy$350.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Wells FargoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016FBR & Co.Reiterated RatingHold$192.00 -> $200.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Leerink SwannReiterated RatingHold$144.00 -> $140.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016BMO Capital MarketsReiterated RatingBuy$221.00 -> $219.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016OppenheimerReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016BarclaysReiterated RatingBuy$200.00 -> $205.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Credit SuisseReiterated RatingBuy$200.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Morgan StanleyReiterated RatingUnderweight$80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016JMP SecuritiesReiterated RatingMarket Outperform$200.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Cowen and CompanyBoost Price TargetOutperform$212.00 -> $215.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Goldman SachsBoost Price TargetNeutral$114.00 -> $128.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/9/2016Bank of AmericaReiterated RatingSell$144.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2016S&P Equity ResearchReiterated RatingAverage$100.60 -> $111.91View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Janney Montgomery ScottReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015RBC CapitalReiterated RatingOutperform$490.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/1/2015MLV & Co.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/27/2015Deutsche BankBoost Price TargetBuy$300.00 -> $400.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/20/2015NomuraSet Price TargetBuy$440.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2014Sterne Agee CRTInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2014Summer StreetReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/5/2016Q1($3.60)($5.17)$0.64 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q415($3.15)($3.62)$0.43 million$0.45 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($2.74)($2.10)$0.42 million$0.45 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($1.95)($1.99)$2.17 million$0.45 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($1.75)($1.78)$1.70 million$1.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($1.53)($1.63)$0.42 million$0.04 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q3($1.02)($1.69)$0.46 million$0.45 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.12)($0.79)$400.00 million$405.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014($0.72)($1.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2014Q4 13($0.70)($0.64)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2013Q313($0.51)($1.65)$0.89 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2013Q2 2013($0.51)($0.79)$0.40 million$0.41 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($4.29)($3.65)($3.83)
Q2 20165($4.12)($3.00)($3.65)
Q3 20164($4.72)($3.17)($3.92)
Q4 20164($4.50)($2.87)($3.87)
Q1 20171($4.19)($4.19)($4.19)
Q2 20171($4.04)($4.04)($4.04)
Q3 20171($3.82)($3.82)($3.82)
Q4 20171($3.52)($3.52)($3.52)
(Data provided by Zacks Investment Research)
Dividend History for Intercept Pharmaceuticals (NASDAQ:ICPT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/25/2016Lisa BrightInsiderSell251$137.50$34,512.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Rachel McminnInsiderSell130$147.49$19,173.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Barbara Gayle DuncanCFOSell144$130.76$18,829.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016David ShapiroCMOSell165$130.76$21,575.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Lisa BrightInsiderSell153$130.76$20,006.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Mark PruzanskiCEOSell708$130.76$92,578.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2016Lisa BrightInsiderSell241$115.22$27,768.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Rachel McminnInsiderSell128$103.56$13,255.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2016Lisa BrightinsiderSell728$125.52$91,378.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Barbara Gayle DuncanCFOSell468$145.90$68,281.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016David ShapiroCMOSell533$145.90$77,764.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Mark PruzanskiCEOSell2,126$145.90$310,183.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Rachel McminnInsiderSell469$145.90$68,427.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2015Lisa BrightInsiderSell1,150$182.96$210,404.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015David ShapiroCMOSell4,264$178.53$761,251.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015David ShapiroCMOSell3,500$204.15$714,525.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015Klaus R. Dr VeitingerDirectorSell1,000$198.25$198,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Rachel McminnInsiderSell125$160.24$20,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2015Barbara Gayle DuncanCFOSell1,054$163.17$171,981.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2015David ShapiroCMOSell1,140$160.12$182,536.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Nicole WilliamsDirectorSell973$194.82$189,559.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015David ShapiroCMOSell3,500$191.28$669,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015David ShapiroCMOSell4,272$209.37$894,428.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Nicole WilliamsDirectorSell973$279.01$271,476.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2015Mark PruzanskiCEOSell12,500$250.00$3,125,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Luciano AdoriniInsiderSell4,067$579.93$2,358,575.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Barbara Gayle DuncanCFOSell1,000$242.10$242,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015David ShapiroCMOSell3,781$238.66$902,373.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Nicole WilliamsDirectorSell974$265.14$258,246.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015David ShapiroCMOSell3,500$241.58$845,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Luciano AdoriniInsiderSell4,000$248.40$993,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Klaus R Dr VeitingerDirectorSell391$279.07$109,116.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2015Luciano AdoriniInsiderSell4,000$259.97$1,039,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Nicole WilliamsDirectorSell974$278.50$271,259.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2015Luciano AdoriniInsiderSell4,000$269.64$1,078,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015David ShapiroCMOSell3,459$275.25$952,089.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/26/2015Orbimed Advisors LlcDirectorSell157,200$286.75$45,077,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2015Orbimed Advisors LlcDirectorSell207,800$274.41$57,022,398.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2015Jonathan SilversteinDirectorSell45,600$272.00$12,403,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Jonathan SilversteinDirectorSell159,400$275.18$43,863,692.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015David ShapiroCMOSell3,500$286.90$1,004,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Klaus R Dr VeitingerDirectorSell233$150.01$34,952.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Barbara Gayle DuncanCFOSell141$176.49$24,885.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Daniel Paul ReganInsiderSell146$176.49$25,767.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015David ShapiroCMOSell664$172.63$114,626.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Mark PruzanskiCEOSell461$176.49$81,361.89View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Barbara Gayle DuncanCFOSell1,000$156.40$156,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014David ShapiroCMOSell4,790$158.82$760,747.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Srinivas AkkarajuDirectorBuy2,000$167.19$334,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Klaus R Dr VeitingerDirectorSell233$175.95$40,996.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Mark PruzanskiCEOSell10,000$259.41$2,594,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Klaus R Dr VeitingerDirectorSell391$223.65$87,447.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2014David ShapiroCMOSell5,020$231.63$1,162,782.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Barbara Gayle DuncanCFOSell1,000$233.12$233,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014David ShapiroCMOSell4,188$231.17$968,139.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Mark PruzanskiCEOSell10,000$228.82$2,288,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014David ShapiroCMOSell4,000$281.19$1,124,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Klaus R Dr VeitingerDirectorSell391$280.50$109,675.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Mark PruzanskiCEOSell10,000$286.49$2,864,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014David ShapiroCMOSell10,000$293.93$2,939,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Orbimed Advisors LlcDirectorSell111,258$298.06$33,161,559.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Jonathan SilversteinDirectorSell50,000$295.59$14,779,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014David ShapiroCMOSell4,774$291.49$1,391,573.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Daniel Paul ReganInsiderSell8,124$325.70$2,645,986.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Klaus R Dr VeitingerDirectorSell316$345.62$109,215.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Mark PruzanskiCEOSell10,000$226.72$2,267,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Klaus R Dr VeitingerDirectorSell391$219.15$85,687.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Lorenzo TallarigoDirectorSell2,000$243.06$486,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2014David ShapiroCMOSell5,036$244.73$1,232,460.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Mark PruzanskiCEOSell10,000$250.61$2,506,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014David ShapiroCMOSell4,000$278.15$1,112,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Mark PruzanskiCEOSell10,000$230.60$2,306,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014Lorenzo TallarigoDirectorSell2,007$254.68$511,142.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Mark PruzanskiCEOSell10,000$263.17$2,631,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2014Mark PruzanskiCEOSell10,000$242.22$2,422,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2014Barbara Gayle DuncanCFOSell1,154$279.00$321,966.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2014Lorenzo TallarigoDirectorSell349,318$317.71$110,981,821.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/9/2014Orbimed Advisors LlcDirectorSell81,305$320.00$26,017,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2014Luciano AdoriniInsiderSell2,000$283.90$567,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014David ShapiroCMOSell5,393$331.83$1,789,559.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2014David ShapiroCMOSell4,456$437.49$1,949,455.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Paolo FundaroDirectorSell7,246$375.26$2,719,133.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2014Mark PruzanskiCEOSell10,000$273.68$2,736,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2014Srinivas AkkarajuDirectorSell3,250$267.94$870,805.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2014David ShapiroCMOSell4,928$71.85$354,076.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2014Lorenzo TallarigoDirectorSell1,839$67.41$123,966.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2014Luciano AdoriniInsiderSell1,634$67.41$110,147.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2013David ShapiroCMOSell5,016$62.11$311,543.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2013Francesco MicheliMajor ShareholderSell124,912$62.50$7,807,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2013Jonathan SilversteinDirectorSell40,088$62.50$2,505,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2013Luciano AdoriniInsiderSell2,000$55.51$111,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2013Francesco MicheliMajor ShareholderSell1,123,415$62.50$70,213,437.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2013Orbimed Advisors LlcDirectorSell376,585$62.50$23,536,562.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2013David ShapiroCMOSell4,392$72.80$319,737.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/20/2013Luciano AdoriniInsiderSell2,000$61.07$122,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2013Mark PruzanskiCEOSell25,000$52.00$1,300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Mark PruzanskiCEOSell12,500$49.02$612,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Luciano AdoriniInsiderSell2,000$44.18$88,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013David ShapiroCMOSell5,016$49.20$246,787.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2013David ShapiroCMOSell4,754$45.04$214,120.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Mark PruzanskiCEOSell12,500$45.98$574,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Paolo FundaroDirectorSell4,759$46.13$219,532.67View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2013Luciano AdoriniInsiderSell2,000$49.44$98,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013Mark PruzanskiCEOSell25,000$50.05$1,251,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2013Mark PruzanskiCEOSell37,500$46.36$1,738,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2013Barbara Gayle DuncanCFOSell25,000$45.39$1,134,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2013David ShapiroCMOSell4,369$43.63$190,619.47View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2013Mark PruzanskiCEOSell12,500$40.06$500,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2013Luciano AdoriniInsiderSell2,000$37.07$74,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2013Mark PruzanskiCEOSell25,000$38.25$956,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013Barbara Gayle DuncanCFOSell50,575$34.50$1,744,837.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2013David ShapiroCMOSell5,016$32.72$164,123.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Barbara Gayle DuncanCFOSell6,225$34.50$214,762.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2013Barbara Gayle DuncanCFOSell28,200$34.50$972,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013David ShapiroCMOSell5,016$31.31$157,050.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/9/2013David ShapiroCMOSell3,750$34.41$129,037.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2012Jonathan SilversteinDirectorBuy333,334$15.00$5,000,010.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Intercept Pharmaceuticals (NASDAQ:ICPT)
DateHeadline
06/29/16 04:31 PMCheck on EPS Growth for: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Telanagana Press
06/29/16 04:31 PMIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Stock Performance and Session Recap - Engelwood Daily
06/29/16 04:31 PMIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Earnings Review and Target Focus - Telanagana Press
06/29/16 04:31 PMIntercept Pharma (ICPT) Announces Aggregate $400M Conv. Senior Notes Offering - StreetInsider.com
06/29/16 04:16 PMAfter The Close: Tractor Supply, Seagate, Google VC, Intercept Pharma - [at Investor's Business Daily] - Seagate Technology (STX) announced layoffs, while Tractor Supply (TSCO) slashed guidance and drugmaker Intercept Pharmaceuticals (ICPT) announced a debt offering. Seagate Technology Seagate Technology ...
06/29/16 03:41 PMIntercept Pharmaceuticals Announces Public Offering of Convertible Senior Notes - [at noodls] - NEW YORK, June 29, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced today that it has commenced an underwritten public offering of $400 million aggregate principal amount ...
06/29/16 07:24 AMIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Broker Price Targets For The Coming Week - Fiscal Standard
06/29/16 07:24 AMIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT)View on Wall Street Analyst Ratings - Engelwood Daily
06/29/16 07:24 AMIntercept Pharmaceuticals Inc (NASDAQ:ICPT)'s Company Shares Decreased 7.83% After High Volatility - Press Telegraph
06/28/16 04:31 PMIntercept Pharmaceuticals Finds Resistance
06/28/16 04:02 PMINTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers -
06/28/16 09:27 AMTechnical Analysis on Biotechnology Equities -- Seattle Genetics, CTI BioPharma, Five Prime Therapeutics, and Intercept Pharma
06/27/16 07:39 AMIntercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : June 27, 2016 -
06/26/16 03:59 PMStock Performance Focus on: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Press Telegraph
06/26/16 03:59 PMStock Sentiment Review for :Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Press Telegraph
06/24/16 04:36 PMTracking Share Activity for: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Press Telegraph
06/24/16 04:36 PMImpact Score Outlook on:Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Press Telegraph
06/24/16 04:36 PMConsensus View on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Stock and Check on Movement - Press Telegraph
06/24/16 07:11 AMNational Planning Corp Increased Intercept Pharmaceuticals In (NASDAQ:ICPT) by $3.23 Million as Shares Declined - Press Telegraph
06/24/16 07:11 AMIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Earnings Glance and Target Price Review - Engelwood Daily
06/23/16 07:28 AMIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Stock Momentum Hits Weakness - CML News
06/22/16 09:14 AMStrong Buy Calls Count For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) At 8 - Investor Newswire
06/17/16 11:05 AMIntercept Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ICPT) : June 17, 2016 -
06/16/16 08:51 AMRecently Issued Stock Ratings For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Fiscal Standard
06/14/16 07:32 AMIntercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : June 14, 2016 -
06/11/16 04:39 PMIntercept Pharma (ICPT) Says Sandip Kapadia Will Succeed Barbara Duncan as CFO
06/10/16 05:03 AMINTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure -
06/09/16 04:46 PMIntercept Pharma (ICPT) Says Sandip Kapadia Will Succeed Barbara Duncan as CFO - StreetInsider.com
06/09/16 04:35 PMIntercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer - [GlobeNewswire] - NEW YORK, June 09, 2016-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, ...
06/09/16 07:15 AMJMP Securities Maintains Intercept Pharmaceuticals Inc to Market Outperform - Trade Calls
06/08/16 04:51 PMINTERCEPT PHARMACEUTICALS INC. (NASDAQ:ICPT) Financial Condition Compared to S&P 500 - CML News
06/07/16 04:44 PMMorgan Stanley Maintains Intercept Pharmaceuticals Inc to Underweight - Trade Calls
06/06/16 04:28 PMThe Two Most Buy Stocks: Cigna Corp. (NYSE:CI), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Beacon Chronicle
06/06/16 08:07 AMInvestors Focused Stocks: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) , Nanosphere, Inc. (NASDAQ:NSPH) - Street Updates
06/05/16 04:31 PMNext Weeks Broker Price Targets For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Share Trading News
06/04/16 04:35 PMIntercept Pharmaceuticals Inc (ICPT) Receives Buy Rating from Barclays - Let Me Know About This
06/04/16 04:35 PMIntercept Pharmaceuticals Inc (ICPT) Rating Reiterated by Oppenheimer - Let Me Know About This
06/04/16 07:18 AMIntercept Pharmaceuticals Inc. (ICPT) is Trading Higher on Unusual Volume for June 02 - Equities.com
06/04/16 07:18 AMIntercept Pharmaceuticals Inc (ICPT) Receives Buy Rating from BMO Capital Markets - Let Me Know About This
06/03/16 04:54 PMSentiment Score Update: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - HNN
06/03/16 04:54 PMTrade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's "Perilous Reversal" Stock - TheStreet.com
06/03/16 07:14 AMHC Stocks to Track: Celldex Therapeutics, Inc. (NASDAQ:CLDX), Intercept Pharmaceuticals Inc (NASDAQ:ICPT) - share market updates (press release) - HC Stocks to Track: Celldex Therapeutics, Inc. (NASDAQ:CLDX), Intercept Pharmaceuticals Inc (NASDAQ:ICPT)share market updates (press release)Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) ended Thursday session in green amid volatile trading. The shares closed up +0.45 points or 9.89% at $5.00 with 4.43 million shares getting traded. Post opening the session at $4.55, the shares hit an ...and more »
06/03/16 07:14 AMTrade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's Post-Market Leader Stock - TheStreet.com - Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's Post-Market Leader StockTheStreet.comIntercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Currently there are 7 analysts that rate Intercept Pharmaceuticals a buy, 2 ...and more »
06/02/16 04:49 PMIntercept Pharmaceuticals Inc Overtakes CymaBay Therapeutics Inc on PBC, Here's Why - Business Finance News - Business Finance NewsIntercept Pharmaceuticals Inc Overtakes CymaBay Therapeutics Inc on PBC, Here's WhyBusiness Finance NewsOn the other hand, Intercept Pharmaceuticals Inc.'s (NASDAQ:ICPT) Ocaliva is ready to launch next week. Keeping this stance under observation, JMP Securities reiterated its Outperform rating on the company's shares with a $170 price target. MBX-8025 is ...and more »
06/02/16 07:19 AMBuy, Sell Or Hold Rating For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)? - Share Trading News - Buy, Sell Or Hold Rating For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)?Share Trading News06/01/2016 – Intercept Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 200 price target on the stock. 06/01/2016 – Intercept Pharmaceuticals, Inc. had its “overweight” rating ...and more »
06/01/16 04:52 PMActive Stock Review: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - HNN - Active Stock Review: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)HNNRecent trading activity of Intercept Pharmaceuticals, Inc.(NASDAQ:ICPT) gets the stock on the active list for today. Shares have changed 4.33% since the open at the time of writing. After a recent look, the stock had hit $154.92. Company shares have ...and more »
06/01/16 04:52 PMComprehensive Report on: Ingersoll-Rand Plc (NYSE:IR), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Beacon Chronicle - Beacon ChronicleComprehensive Report on: Ingersoll-Rand Plc (NYSE:IR), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)Beacon ChronicleLast Trade: The Company closed its last session at $66.81 with the gain of 0.5%. The market capitalization of the company is $17.15 Billion, with the average Volume of 1.82 Million. The stock currently has its 52-Week High range of $70.47 and 52-week ...and more »
06/01/16 04:52 PMStock Sentiment Update:Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - HNN - Stock Sentiment Update:Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)HNNIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has a current news sentiment score of 0.404. This data is given by Beta Research. On a scale between 1 and -1, a score of 1 would represent the news sentiment being positive. On the opposite side, a score ...and more »
06/01/16 04:52 PMAnalyst Update: Intercept Pharmaceuticals Inc, Relypsa Inc, and Myriad Genetics, Inc. - Schaeffers Research (blog) - Schaeffers Research (blog)Analyst Update: Intercept Pharmaceuticals Inc, Relypsa Inc, and Myriad Genetics, Inc.Schaeffers Research (blog)Analysts are weighing in on biotech stocks Intercept Pharmaceuticals Inc (NASDAQ:ICPT) and Relypsa Inc (NASDAQ:RLYP), as well as molecular diagnostics firm Myriad Genetics, Inc. (NASDAQ:MYGN). Here's a quick roundup of today's brokerage notes on ...Two Analysts Share Views On What's In Store For Relypsa Inc (RLYP) And Intercept Pharmaceuticals Inc (ICPT)Smarter Analystall 41 news articles »
06/01/16 04:52 PMIntercept Pharmaceuticals Inc (ICPT) Sees Unusually-High Trading Volume Following Analyst Upgrade - Let Me Know About This - TheStreet.comIntercept Pharmaceuticals Inc (ICPT) Sees Unusually-High Trading Volume Following Analyst UpgradeLet Me Know About ThisIntercept Pharmaceuticals logo Intercept Pharmaceuticals Inc (NASDAQ:ICPT) saw an uptick in trading volume on Wednesday after Cowen and Company raised their price target on the stock from $212.00 to $215.00. Cowen and Company currently has an ...Stock in a Downward Trend: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)Franklin IndependentGoldman Sachs Boosts Intercept Pharmaceuticals Inc (ICPT) Price Target to $128.00The Cerbat GemHeavy Trading On Intercept Pharmaceuticals (ICPT) Before Market OpenTheStreet.comZergwatch -Is stories -Seneca Globeall 40 news articles »
About Intercept Pharmaceuticals

Intercept Pharmaceuticals logoIntercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials, including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ICPT
  • CUSIP: 45845P10
Key Metrics:
  • Previous Close: $149.87
  • 50 Day Moving Average: $144.60
  • 200 Day Moving Average: $134.50
  • P/E Ratio: N/A
  • P/E Growth: -1.13
  • Market Cap: $3.69B
  • Current Quarter EPS Consensus Estimate: $-16.48 EPS
Additional Links:
Intercept Pharmaceuticals (NASDAQ:ICPT) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha